Inappropriate Therapy of Subcutaneous Implantable Cardioverter-Defibrillator Induced by an Electrical Bath.

Intern MedMar 17, 2026 (epub)
Case ReportCardiology

Motohiro Shingu, Tatsuya Nishikawa, Ryouta Yoshioka et al.

✦ AI-curated · Sources linked

Case in brief

A 73-year-old man with a subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of ventricular fibrillation received an inappropriate shock while using a Japanese electric bath (denki buro). Device interrogation showed that electrical waves from the bath had triggered the therapy. The report identifies the bath exposure as the source of the inappropriate shock and highlights the need to address this risk when educating patients with an S-ICD.

What made this case unusual

The inappropriate S-ICD therapy was triggered by electrical waves from a Japanese electric bath, an environmental source of interference identified on device interrogation.

Diagnostic / clinical pearl

When an S-ICD delivers an inappropriate shock, device interrogation can help identify environmental electrical interference; ask about exposure to electric baths.

Why it matters

The authors note that S-ICDs may be more sensitive than transvenous ICDs because of electrode position, supporting specific patient education about electric-bath exposure.

Source

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.